

Applicants: Pablo Rubinstein et al.
Serial No.: 09/855,789
Filed: May 15, 2001
Page 2

Amendments to the Claims:

Please cancel Claims 33, 48, 49, and 54-73 without prejudice or disclaimer, amend Claims 25, 34, 36, and 41, and add new claims 74-77 as set forth below.

1-24. (Canceled)

25. (Currently Amended) A therapeutic product obtained from cord blood or placental blood, wherein the therapeutic product comprises white blood cells, less than all of plasma contained in said cord blood or placental blood, less than 10% ~~all~~ of red blood cells contained in said cord blood or placental blood, and a cryoprotective agent, wherein the therapeutic product is characterized by a white cell viability greater than 80% with respect to said cord blood or placental blood.

26. (Canceled)

27. (Previously presented) The therapeutic product of Claim 25, wherein said cryoprotective agent comprises dimethyl sulfoxide.

28. (Previously presented) The therapeutic product of Claim 25, wherein said cryoprotective agent comprises dextran.

29. (Previously presented) The therapeutic product of Claim 27, wherein said dimethyl sulfoxide is diluted to 50% with dextran.

30. (Previously presented) The therapeutic product of Claim 27, wherein a concentration of said dimethyl sulfoxide is not greater than 10%.

31. (Previously presented) The therapeutic product of Claim 27, wherein a concentration of said dimethyl sulfoxide is not greater than 1%.

32. (Previously presented) The therapeutic product of Claim 27, wherein an osmolarity of said product is not more than 300 milliosmols.

33. (Canceled)

34. (Currently amended) The therapeutic product of Claim 25, wherein the therapeutic product is characterized by a white cell viability greater than 90% with respect to said cord blood or placental blood.

35. (Previously presented) The therapeutic product of Claim 25, wherein the therapeutic product comprises an anticoagulant.

36. (Currently amended) The therapeutic product of Claim 35, wherein the anticoagulant is Citrate, Phosphate, and Dextrose (CPD).

37-38. (Canceled)

39. (Previously presented) The therapeutic product of Claim 25, wherein white cell viability is tested using DNA fluorescence stain.

40. (Previously presented) The therapeutic product of Claim 25, wherein the therapeutic product is contained in a volume of 3 milliliters to 20 milliliters.

41. (Currently amended) A therapeutic product obtained from cord blood or placental blood, wherein the therapeutic product comprises thawed ~~consists essentially~~ of white blood cells, less than all of plasma contained in said cord blood or placental blood, less than 10% ~~all~~ of red blood cells contained in said cord blood or placental blood, and a cryoprotective agent, wherein the thawed white blood cells have a viability greater than 90% with respect to said cord blood or placental blood. ~~wherein the therapeutic product is characterized by a white cell viability greater than 80%.~~

42. (Previously presented) The therapeutic product of Claim 41, wherein said cryoprotective agent comprises dimethyl sulfoxide.

43. (Previously presented) The therapeutic product of Claim 41, wherein said cryoprotective agent comprises dextran.

44. (Previously presented) The therapeutic product of Claim 42, wherein said dimethyl sulfoxide is diluted to 50% with dextran.

45. (Previously presented) The therapeutic product of Claim 42, wherein a concentration of said dimethyl sulfoxide is not greater than 10%

46. (Previously presented) The therapeutic product of Claim 42, wherein a concentration of said dimethyl sulfoxide is not greater than 1%.

47. (Previously presented) The therapeutic product of Claim 42, wherein an osmolarity of said product is not more than 300 milliosmols.

48-51. (Canceled)

52. (Previously presented) The therapeutic product of Claim 41, wherein white cell viability is tested using DNA fluorescence stain.

53. (Previously presented) The therapeutic product of Claim 41, wherein the therapeutic product is contained in a volume of 3 milliliters to 20 milliliters.

54-73. (Canceled)

74. (New) The therapeutic product of Claim 41, wherein the therapeutic product comprises an anticoagulant.

75. (New) The therapeutic product of Claim 41, wherein the anticoagulant is Citrate, Phosphate, and Dextrose (CPD).

76. (New) The therapeutic product of Claim 25, wherein the red cell to white cell count is approximately one hundred (100) to one (1).

77. (New) The therapeutic product of Claim 41, wherein the red cell to white cell count is approximately one hundred (100) to one (1).